Covance Inc. (CVD) Increases Its Medical And Scientific Leadership With Two Senior-Level Appointments

Dr. Robert Wasserman named Vice President and Global Therapeutic Area Head, Oncology and Dr. Rogelio Mosqueda-Garcia named Global Vice President, Early Clinical Services within Medical & Scientific Affairs 

Princeton, N.J. – July 9, 2014 – Covance today announced two key additions to its clinical development services scientific leadership team with the appointments of Robert Wasserman, M.D., as Vice President and Global Therapeutic Area Head, Oncology and Rogelio Mosqueda-Garcia, M.D., Ph.D., as Global Vice President, Early Clinical Services within Medical & Scientific Affairs. Both are based in Princeton, N.J. 

"With our appointment of these two respected and accomplished leaders in the pharmaceutical industry, we continue to grow Covance's scientific and medical leadership and our expertise across critical therapeutic areas within drug development," said Ken Somberg, M.D., Chief Medical Officer and Vice President, Clinical Development Services. "Covance's medical and scientific affairs team is well positioned to offer guidance and insights in key therapeutic categories such as oncology, where there is a growing number of targets and an emphasis on personalized medicine, as well as in the preclinical to proof-of-concept space, where the focus is on accelerating development, increasing quality and providing more robust data in the decision-making process." 

Dr. Robert Wasserman 

Dr. Wasserman's expertise lies in oncology translational medicine, including preclinical, clinical, biomarker and companion diagnostic drug development. In his new role, he will be responsible for leading the scientific strategy for the oncology and hematology therapeutic areas. 

Before joining Covance, Dr. Wasserman spent 15 years in the pharmaceutical industry, most recently at Hoffmann-La Roche as Site Head of Academic Alliances, Pharma Research and Early Development (pRED) for the Translational Clinical Research Center. He served as Vice President and Personalized Healthcare Strategic Expert for Roche pRED Oncology, where he was responsible for the personalized healthcare strategy across the preclinical and clinical portfolio. As Vice President and Global Head, Translational Medicine for Roche pRED Oncology, he was responsible for bridging discovery and clinical research through the development of translational medicine strategies, conducting early-phase trials, and supporting the personalized healthcare objectives of the organization. Earlier in his career, Dr. Wasserman held increasingly senior-level positions at Merck and Novartis. 

Dr. Wasserman earned his M.D. from Johns Hopkins University School of Medicine, and completed his pediatric residency and pediatric hematology-oncology fellowship training at The Children's Hospital of Philadelphia, University of Pennsylvania. 

"Covance enjoys a strong reputation for the depth and breadth of its experience serving clients in biotechnology and pharmaceuticals," Dr. Wasserman said. "I look forward to working with Covance's talented oncology team as well as the global medical and scientific community across the company." 

Dr. Rogelio Mosqueda-Garcia 

Dr. Mosqueda-Garcia is a prominent clinical pharmacologist with extensive academic and industry experience in several therapeutic areas, as well as in translational and experimental medicine. Dr. Mosqueda-Garcia will provide scientific direction for the Clinical Pharmacology Services and Early Clinical Development groups. He also will work internally and externally to address issues of clinical pharmacology studies in patients, integration of biomarkers in early development, and the creation of novel approaches to establish proof of concept in development programs of new drug candidates. 

Dr. Mosqueda-Garcia previously served as Executive Director in Clinical Pharmacology at AstraZeneca Pharmaceuticals. He held senior roles in the Clinical Discovery Group at Bristol-Myers Squibb and in the Clinical Pharmacology Department at DuPont Pharmaceuticals. Prior to joining the pharmaceutical industry, Dr. Mosqueda-Garcia held faculty appointments at Vanderbilt University in the Clinical Pharmacology Division, Department of Medicine, where he performed basic and clinical research, as well as provided hospital patient care. 

Dr. Mosqueda-Garcia earned his M.D. from the School of Medicine at the National University of Mexico and a Ph.D. in Pharmacology from McGill University in Montreal, Quebec, Canada. He also has formal fellowship training in clinical pharmacology and in autonomic dysfunction from Vanderbilt University. 

"Covance's commitment to operational, scientific and service excellence ensures it will continue to grow and provide comprehensive solutions to clients," Dr. Mosqueda-Garcia said. "I am very excited to join Covance and contribute to its future success in critical areas of early drug development." 

About Covance

Covance, the world's most comprehensive drug development company and a leader in nutritional analysis, is dedicated to advancing healthcare and delivering Solutions Made RealTM. The company, headquartered in Princeton, New Jersey, has annual revenues greater than $2.4 billion and more than 12,500 employees located in over 60 countries. Information on Covance's solutions, recent press releases, and SEC filings can be obtained through its website at 

Forward Looking Statements

Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.